AC BioScience closes second Seed Round for CHF 1 million
AC BioScience, a Lausanne-based biotech company pioneering the development of novel therapies in immuno-oncology and tumor vascular normalisation, is pleased to announce the successful closure of its second Seed Round for a total amount of CHF 1 million. This bridge funding precedes a planned Series A round in late 2020 to finance clinical trials. AC BioScience will also present at the 9th International Cancer Cluster Showcase
- BIO 2020 on 8 June 2020.